This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.80% per year. These returns cover a period from January 1, 1988 through August 3, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
medical-devices: Archive
BDX Deploys Vmax 160 to Advance Intelligent Pharmacy Automation
by Zacks Equity Research
BD expands U.S. pharmacy automation with Vmax 160 at Fairview to handle complex specialty and refrigerated medications.
BDXNegative Net Change WSTNegative Net Change GMEDNegative Net Change VCYTNegative Net Change
medical medical-devices
ISRG's da Vinci Study Shows Better Outcomes Across 13 Common Conditions
by Zacks Equity Research
Intuitive Surgical's da Vinci meta-analysis across 14 million procedures found better perioperative outcomes versus laparoscopic and open surgery.
ISRGPositive Net Change WSTNegative Net Change GMEDNegative Net Change VCYTNegative Net Change
medical medical-devices
Should Investors Add EYE Stock to Their Portfolios Now?
by Zacks Equity Research
National Vision's premium-product demand and stronger customer mix support growth, but rising costs and vendor dependence remain key risks for investors.
EYEPositive Net Change TFXNegative Net Change GMEDNegative Net Change VCYTNegative Net Change
medical medical-devices
Implied Volatility Surging for AMN Healthcare Stock Options
by Zacks Equity Research
Investors need to pay close attention to AMN stock based on the movements in the options market lately.
AMNNegative Net Change
medical medical-devices
Here's Why You Should Retain DexCom Stock in Your Portfolio for Now
by Zacks Equity Research
DXCM's strong growth, G7 15 Day adoption and CONNECT trial could expand its CGM market opportunity despite reimbursement and competition risks.
DXCMPositive Net Change WSTNegative Net Change GMEDNegative Net Change VCYTNegative Net Change
medical medical-devices
Can AI Keep ISRG Ahead of Rising Robotic Surgery Competition?
by Indrajit Bandyopadhyay
ISRG is using AI, software, data and advanced instruments to strengthen da Vinci 5 and stay ahead as robotic surgery competition intensifies.
ISRGPositive Net Change STXSPositive Net Change GMEDNegative Net Change
medical medical-devices
Here's Why Tenet Healthcare Shares are Attracting Investors Now
by Zacks Equity Research
THC's shares are gaining on higher-acuity demand, strong commercial revenues and USPI's continued expansion.
THCPositive Net Change UNHPositive Net Change CNCNegative Net Change GMEDNegative Net Change
artificial-intelligence automation medical medical-devices robotics smart-health
BLCO Gains European CE Mark for Next-Gen SeeLyra Femtosecond Laser
by Zacks Equity Research
Bausch + Lomb gains European CE Mark approval for SeeLyra, expanding its surgical portfolio with a compact laser platform for cataract and corneal procedures.
BLCOPositive Net Change WSTNegative Net Change GMEDNegative Net Change VCYTNegative Net Change
medical medical-devices
Should You Continue to Hold ALGN Stock in Your Portfolio?
by Zacks Equity Research
Align Technology expands Invisalign and digital dentistry adoption as iTero gains traction, but weak capital spending and currency volatility remain risks.
ALGNNegative Net Change TFXNegative Net Change GMEDNegative Net Change VCYTNegative Net Change
medical medical-devices
Boston Scientific Leans on Acquisitions to Drive Long-Term Growth
by Moumi Mondal
BSX's deal-making push expands its reach into high-growth markets, with Penumbra adding a major thrombectomy opportunity.
BSXNegative Net Change MDTNegative Net Change SYKNegative Net Change
medical medical-devices